↓ Skip to main content

Dove Medical Press

Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#50 of 524)
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
1 X user

Readers on

mendeley
34 Mendeley
Title
Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
Published in
ClinicoEconomics and Outcomes Research: CEOR, November 2015
DOI 10.2147/ceor.s88531
Pubmed ID
Authors

Enrica Menditto, Valentina Orlando, Silvia Coretti, Daria Putignano, Denise Fiorentino, Matteo Ruggeri

Abstract

Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies cannot overlook their active role in determining health care resource allocation. This paper addresses this issue, investigating the effects of cost containment measures in the market of biosimilar drugs that represent a viable and cost-saving strategy for the reduction of health care expenditure. The analysis focuses on a particular region in Italy, where several timely policies to incentivize biosimilar prescribing were launched. Drugs were identified by the anatomical therapeutic chemical classification system. Information about biosimilar drugs and their originator biological products was extracted from the IMS Health regional database. Drug consumption was expressed in terms of counting units, while expenditure was evaluated in Euro (€). The market penetration of biosimilars was analyzed by year and quarterly. In the Campania region of Italy, the effects of cost containment policies, launched between 2009 and 2013, showed the prescription of biosimilars strongly increasing in 2010 until prescribing levels reached and exceeded the market share of the reference biological products in 2012. After a slight reduction, a plateau was observed at the beginning of 2013. At the same time, the use of the originator products had been decreasing until the first quarter of 2011. However, after a 1-year plateau, this trend was reversed, with a new increase in the consumption of the originators observed. Results show that the cost containment policies, applied to cut health expenditure "to cure and not to care", did not produce the cultural change necessary to make these policies effective in the long run. Therefore, top-down policies for cost containment are not successful; rather, a bottom-up approach based on consensus among professionals should become the preferred option.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 24%
Researcher 8 24%
Other 4 12%
Student > Ph. D. Student 3 9%
Student > Postgraduate 2 6%
Other 1 3%
Unknown 8 24%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 8 24%
Medicine and Dentistry 5 15%
Economics, Econometrics and Finance 3 9%
Nursing and Health Professions 2 6%
Social Sciences 2 6%
Other 6 18%
Unknown 8 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 August 2018.
All research outputs
#2,437,175
of 25,584,565 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#50
of 524 outputs
Outputs of similar age
#33,610
of 295,303 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#2
of 17 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 524 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,303 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.